The GOLGA2 Knockout AGS Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population in which the GOLGA2 gene is disrupted. This yields a mixture of edited alleles, creating a robust loss-of-function model for studying GM130, a key Golgi matrix protein. The polyclonal format avoids the limitations of single-cell clones and preserves phenotypic diversity, making it suitable for population-level assays.
The host AGS cell line is derived from a human gastric adenocarcinoma and exhibits epithelial morphology. It serves as a widely used model for gastric cancer biology, including studies on tumor cell migration, invasion, and secretory pathways. AGS cells are particularly appropriate for investigating Golgi-related pathologies because their transformed phenotype amplifies defects in membrane trafficking and cell cycle control.
GOLGA2 encodes GM130, an essential cis-Golgi matrix component. GM130 interacts with GORASP1 (GRASP65) to form Golgi cisternal stacks and with USO1 (p115) to tether COPI transport vesicles. Its activity is regulated by mitotic kinases CDK1 and PLK1, which phosphorylate GM130 to drive mitotic Golgi disassembly. Downstream, the protein facilitates Golgi reassembly post-mitosis and vesicle docking, while RAB1 and SNARE proteins mediate fusion steps. Disruption of GOLGA2 therefore compromises Golgi ribbon integrity, impairs protein secretion, and leads to cell cycle defects through aberrant mitotic progression.
In the AGS gastric cancer context, knockout of GOLGA2 provides a model to link Golgi dysfunction to tumor progression. Loss of GM130 can alter the secretion of matrix remodeling enzymes and growth factors, potentially affecting invasion and proliferation. Aberrant Golgi disassembly and cell cycle defects may also sensitize cells to therapeutic agents targeting mitotic kinases or vesicle trafficking. Thus, this polyclonal knockout model enables detailed exploration of how Golgi matrix disruption influences gastric adenocarcinoma phenotypes, including drug resistance and metastatic behavior.
Researchers can employ this model in a variety of experiments. Immunofluorescence and electron microscopy reveal changes in Golgi ultrastructure, while Western blotting and RT-qPCR confirm target gene disruption and protein loss. Co-immunoprecipitation assays with GRASP65 or USO1 assess altered protein interactions. Functional studies include flow cytometry for cell cycle distribution, transwell migration and invasion assays, and secretion assays using reporter cargoes. These approaches support mechanistic studies of Golgi biology and preclinical testing of Golgi-directed therapies. For additional information or custom inquiries, please reach out to Ascent Research.
